Discussion among autism researchers on Twitter this week swirled around how well pediatricians assess the condition, how it affects cognitive aging and how it alters cardiometabolic disease risk.

The findings put genetic background forward to help explain autism’s heterogeneity.

Elsevier’s retractions focus on peer review and conflicts of interest.

The gene, linked to a little-known condition called Weiss-Kruszka syndrome, prevents embryonic stem cells from deviating from their neuronal destiny.

Altered expression of TSC2 and the mTOR pathway reshape the formation of certain synapses between inhibitory and excitatory neurons in mice.

Conversation took off this week around precision in neuroscience measurements, a new strategy to rescue Rett neurons, autism insights from protein interactomes, and mechanisms of touch perception.

CRISPR-edited prairie voles that lack receptors for the so-called “social hormone” still bond with their mate and pups, raising questions about the molecule’s role.

Serious differences in autism identification persist, according to an analysis of autistic children in New Jersey over 16 years.

Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.

Cells from people with fragile X syndrome overproduce — but don’t accumulate — proteins. New work suggests that excessive protein breakdown may account for this discrepancy, and explain some of the syndrome’s traits.